Examiner: SAJJADI, FEREYDOUN GHOTB

Tech Center 1600 • Art Units: 1617 1622 1633 1671 1699

This examiner grants 42% of resolved cases

Performance Statistics

42.0%

Allow Rate

-18.0% vs TC avg

Total Applications

+47.8%

Interview Lift

1308

Avg Prosecution Days

Based on 81 resolved cases, 2023–2026

2.5%

§101 Eligibility

13.1%

§102 Novelty

64.8%

§103 Obviousness

12.3%

§112 Clarity

App #	Title	Status	Assignee
18952618	USE OF PLINABULIN IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS	Final Rejection	BeyondSpring Pharmaceuticals, Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.